Non-Discrimination Notice

EnzaRadicate

EnzaRadicate – A study of Enzalutamide and Radium 223 dichloride in castration resistant prostate cancer subjects with symptomatic bone metastases

Some Requirements:

1. Subject is male, greater than 18 years at a time
2. Documented prostate cancer with bone metastases and pain
3. PSA above 2.0

Sponsored by: Carolina Research Associates
Length of Study: 2 years
Enrollment: Open

Please contact one of our Clinical Research Coordinators today to find out more information if you are interested in this trial.

Research Department (315) 478-4185, option 7

Our Investigator for this study is Christopher Pieczonka, M.D.